The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study
BackgroundApatinib and immune checkpoint inhibitors (ICIs) have shown promise as third-line treatments for advanced gastric cancer (AGC). This study compared the efficacy and safety of apatinib combined with ICIs versus apatinib monotherapy in AGC patients after second-line treatment failure.Methods...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1578011/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850130955026563072 |
|---|---|
| author | Peng-Fei Zhu Liu Yang Zhe-Ling Chen |
| author_facet | Peng-Fei Zhu Liu Yang Zhe-Ling Chen |
| author_sort | Peng-Fei Zhu |
| collection | DOAJ |
| description | BackgroundApatinib and immune checkpoint inhibitors (ICIs) have shown promise as third-line treatments for advanced gastric cancer (AGC). This study compared the efficacy and safety of apatinib combined with ICIs versus apatinib monotherapy in AGC patients after second-line treatment failure.MethodsWe conducted a retrospective analysis of 48 AGC patients with postoperative recurrence/metastasis treated at Zhejiang Provincial People’s Hospital between January 2018 and September 2022. Patients received either apatinib plus ICIs (n=23) or apatinib alone (n=25). Primary endpoints were overall survival (OS) and progression-free survival (PFS); Secondary endpoints included safety and subgroup analyses.ResultsWith median follow-up of 4.25 months, the combination group showed significantly longer median OS (6.0 vs 3.0 months, HR=0.44, 95%CI 0.24-0.82, P=0.009) and PFS (3.0 vs 2.0 months, P=0.155). Subgroup analysis revealed patients with liver metastasis receiving combination therapy had superior OS (7.5 vs 4.0 months, P=0.036). The objective response rate was higher with combination therapy (4.3% vs 0%), though not statistically significant (P=0.292). Safety profiles were comparable between groups, with no significant increase in severe adverse events with combination therapy.ConclusionApatinib combined with ICIs demonstrated improved survival outcomes compared to apatinib monotherapy in AGC, particularly for patients with liver metastasis, without increasing severe toxicity. |
| format | Article |
| id | doaj-art-a40efd8f56634ffab4da9dc12fbdabc4 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-a40efd8f56634ffab4da9dc12fbdabc42025-08-20T02:32:33ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15780111578011The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world studyPeng-Fei ZhuLiu YangZhe-Ling ChenBackgroundApatinib and immune checkpoint inhibitors (ICIs) have shown promise as third-line treatments for advanced gastric cancer (AGC). This study compared the efficacy and safety of apatinib combined with ICIs versus apatinib monotherapy in AGC patients after second-line treatment failure.MethodsWe conducted a retrospective analysis of 48 AGC patients with postoperative recurrence/metastasis treated at Zhejiang Provincial People’s Hospital between January 2018 and September 2022. Patients received either apatinib plus ICIs (n=23) or apatinib alone (n=25). Primary endpoints were overall survival (OS) and progression-free survival (PFS); Secondary endpoints included safety and subgroup analyses.ResultsWith median follow-up of 4.25 months, the combination group showed significantly longer median OS (6.0 vs 3.0 months, HR=0.44, 95%CI 0.24-0.82, P=0.009) and PFS (3.0 vs 2.0 months, P=0.155). Subgroup analysis revealed patients with liver metastasis receiving combination therapy had superior OS (7.5 vs 4.0 months, P=0.036). The objective response rate was higher with combination therapy (4.3% vs 0%), though not statistically significant (P=0.292). Safety profiles were comparable between groups, with no significant increase in severe adverse events with combination therapy.ConclusionApatinib combined with ICIs demonstrated improved survival outcomes compared to apatinib monotherapy in AGC, particularly for patients with liver metastasis, without increasing severe toxicity.https://www.frontiersin.org/articles/10.3389/fonc.2025.1578011/fullgastric cancerimmunotherapyapatinibsurvival timeprognosisantiangiogenesis |
| spellingShingle | Peng-Fei Zhu Liu Yang Zhe-Ling Chen The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study Frontiers in Oncology gastric cancer immunotherapy apatinib survival time prognosis antiangiogenesis |
| title | The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study |
| title_full | The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study |
| title_fullStr | The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study |
| title_full_unstemmed | The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study |
| title_short | The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study |
| title_sort | evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer a real world study |
| topic | gastric cancer immunotherapy apatinib survival time prognosis antiangiogenesis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1578011/full |
| work_keys_str_mv | AT pengfeizhu theevaluationoftheefficacyandsafetyaboutapatinibcombinedwithimmunecheckpointinhibitorsinadvancedgastriccancerarealworldstudy AT liuyang theevaluationoftheefficacyandsafetyaboutapatinibcombinedwithimmunecheckpointinhibitorsinadvancedgastriccancerarealworldstudy AT zhelingchen theevaluationoftheefficacyandsafetyaboutapatinibcombinedwithimmunecheckpointinhibitorsinadvancedgastriccancerarealworldstudy AT pengfeizhu evaluationoftheefficacyandsafetyaboutapatinibcombinedwithimmunecheckpointinhibitorsinadvancedgastriccancerarealworldstudy AT liuyang evaluationoftheefficacyandsafetyaboutapatinibcombinedwithimmunecheckpointinhibitorsinadvancedgastriccancerarealworldstudy AT zhelingchen evaluationoftheefficacyandsafetyaboutapatinibcombinedwithimmunecheckpointinhibitorsinadvancedgastriccancerarealworldstudy |